Martín Lázaro
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Martín Lázaro has a total of 287 co-authors. Here are the top co-authors by number of shared publications:
- Alberto Cruz-Bermúdez
Hospital Universitario Puerta de Hierro-Majadahonda, Madrid, Spain
43 shared publications - Alex Martinez-Marti
Medical Oncology Department, Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Hospital Universitari, 08035 Barcelona, Spain
43 shared publications - Amelia Insa
Medical Oncology Department, Hospital Clinico Universitario de Valencia, Valencia, Spain
43 shared publications - Ernest Nadal
Department of Medical Oncology, Institut Català d’Oncologia (ICO), IDIBELL, Bellvitge Healthcare Campus, L’Hospitalet de Llobregat, Barcelona, Spain
43 shared publications - Javier de Castro
Hospital Universitario La Paz, Madrid, Spain
43 shared publications - Virginia Calvo
Medical Oncology Department, Hospital Universitario Puerta de Hierro, Majadahonda, Madrid, Spain
43 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Data from Decoding B-cell Signatures of Complete Pathologic Response to Perioperative Chemoimmunotherapy in Non–Small Cell Lung Cancer
Purpose:Complete pathologic response (CPR) correlates with long-term survival after perioperative chemoimmunotherapy (ChIO) in resectable non–small cell lung cancer (NSCLC). We provide a multiomic characterization of B cells and tertiary lymphoid structures (TLS) to dissect the immune landscape associated with CPR.Experimental Design:We integrated B-cell receptor (BCR) repertoire profiling (n = 87 tissue, n = 25 blood), multiplex immunofluorescence (n = 67), and bulk (n = 15), spatial (n = 12), and single-cell transcriptomics (n = 15) from tumor tissue and blood (baseline, surgery, and at 6 months of adjuvant therapy) in 123 patients (NADIM/NADIM II trials, NCT03081689/NCT03838159).Results:CPR tumors exhibited a more clonal baseline BCR repertoire (AUC 0.775; P = 0.030) that was better conserved and reinvigorated during neoadjuvant ChIO. In blood, patients with CPR tumors displayed a repertoire enriched in class-switched clones (AUC 0.833; P = 0.008), characterized by higher diversity, lower clonality, and upregulation of activation-related transcriptional programs. Neoadjuvant ChIO was associated with the induction of B-cell–related genes within TLS regions and with higher TLS density at surgery compared with Ch (P = 0.034). TLS density was not associated with CPR (P = 0.129); however, mature TLS in CPR tumors were enriched in immune activation and antigen-presenting pathways, estimated T follicular helper cells, plasmacytoid dendritic cells, and plasma cells, whereas low B-cell regions from CPR tumors displayed higher inferred infiltration of CD8+ T cells, NK cells, and macrophages, with reduced neutrophils and Tregs.Conclusions:Patients with CPR tumors exhibit a preexisting and more mature B-cell response that develops further during neoadjuvant ChIO. Our findings link B-cell–related features to CPR and highlight BCR metrics as promising predictive biomarkers in NSCLC.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Decoding B-cell Signatures of Complete Pathologic Response to Perioperative Chemoimmunotherapy in Non–Small Cell Lung Cancer
Purpose:Complete pathologic response (CPR) correlates with long-term survival after perioperative chemoimmunotherapy (ChIO) in resectable non–small cell lung cancer (NSCLC). We provide a multiomic characterization of B cells and tertiary lymphoid structures (TLS) to dissect the immune landscape associated with CPR.Experimental Design:We integrated B-cell receptor (BCR) repertoire profiling (n = 87 tissue, n = 25 blood), multiplex immunofluorescence (n = 67), and bulk (n = 15), spatial (n = 12), and single-cell transcriptomics (n = 15) from tumor tissue and blood (baseline, surgery, and at 6 months of adjuvant therapy) in 123 patients (NADIM/NADIM II trials, NCT03081689/NCT03838159).Results:CPR tumors exhibited a more clonal baseline BCR repertoire (AUC 0.775; P = 0.030) that was better conserved and reinvigorated during neoadjuvant ChIO. In blood, patients with CPR tumors displayed a repertoire enriched in class-switched clones (AUC 0.833; P = 0.008), characterized by higher diversity, lower clonality, and upregulation of activation-related transcriptional programs. Neoadjuvant ChIO was associated with the induction of B-cell–related genes within TLS regions and with higher TLS density at surgery compared with Ch (P = 0.034). TLS density was not associated with CPR (P = 0.129); however, mature TLS in CPR tumors were enriched in immune activation and antigen-presenting pathways, estimated T follicular helper cells, plasmacytoid dendritic cells, and plasma cells, whereas low B-cell regions from CPR tumors displayed higher inferred infiltration of CD8+ T cells, NK cells, and macrophages, with reduced neutrophils and Tregs.Conclusions:Patients with CPR tumors exhibit a preexisting and more mature B-cell response that develops further during neoadjuvant ChIO. Our findings link B-cell–related features to CPR and highlight BCR metrics as promising predictive biomarkers in NSCLC.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from Decoding B-cell Signatures of Complete Pathologic Response to Perioperative Chemoimmunotherapy in Non–Small Cell Lung Cancer
Supplementary Figure 2. BCR repertoire dynamics.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Decoding B-cell Signatures of Complete Pathologic Response to Perioperative Chemoimmunotherapy in Non–Small Cell Lung Cancer
Supplementary Figure 2. BCR repertoire dynamics.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S5 from Decoding B-cell Signatures of Complete Pathologic Response to Perioperative Chemoimmunotherapy in Non–Small Cell Lung Cancer
Supplementary Figure 5. Areas of interest represent different biological entities and differ by pathological response.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from Decoding B-cell Signatures of Complete Pathologic Response to Perioperative Chemoimmunotherapy in Non–Small Cell Lung Cancer
Supplementary Figure 5. Areas of interest represent different biological entities and differ by pathological response.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S8 from Decoding B-cell Signatures of Complete Pathologic Response to Perioperative Chemoimmunotherapy in Non–Small Cell Lung Cancer
Visium DEG per main phenotype by response
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S8 from Decoding B-cell Signatures of Complete Pathologic Response to Perioperative Chemoimmunotherapy in Non–Small Cell Lung Cancer
Visium DEG per main phenotype by response
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S10 from Decoding B-cell Signatures of Complete Pathologic Response to Perioperative Chemoimmunotherapy in Non–Small Cell Lung Cancer
Table S10 from Decoding B-cell Signatures of Complete Pathologic Response to Perioperative Chemoimmunotherapy in Non–Small Cell Lung Cancer
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S10 from Decoding B-cell Signatures of Complete Pathologic Response to Perioperative Chemoimmunotherapy in Non–Small Cell Lung Cancer
Table S10 from Decoding B-cell Signatures of Complete Pathologic Response to Perioperative Chemoimmunotherapy in Non–Small Cell Lung Cancer
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S11 from Decoding B-cell Signatures of Complete Pathologic Response to Perioperative Chemoimmunotherapy in Non–Small Cell Lung Cancer
Supplementary Figure 11. Comparison between Complete Pathological Response (CPR) (N=6) and Non-Complete Pathological Response (NCPR) (N=7) in pre- and post-treatment samples across all other cell types.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S11 from Decoding B-cell Signatures of Complete Pathologic Response to Perioperative Chemoimmunotherapy in Non–Small Cell Lung Cancer
Supplementary Figure 11. Comparison between Complete Pathological Response (CPR) (N=6) and Non-Complete Pathological Response (NCPR) (N=7) in pre- and post-treatment samples across all other cell types.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S4 and S5 from Decoding B-cell Signatures of Complete Pathologic Response to Perioperative Chemoimmunotherapy in Non–Small Cell Lung Cancer
Table S4 and S5 from Decoding B-cell Signatures of Complete Pathologic Response to Perioperative Chemoimmunotherapy in Non–Small Cell Lung Cancer
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S4 and S5 from Decoding B-cell Signatures of Complete Pathologic Response to Perioperative Chemoimmunotherapy in Non–Small Cell Lung Cancer
Table S4 and S5 from Decoding B-cell Signatures of Complete Pathologic Response to Perioperative Chemoimmunotherapy in Non–Small Cell Lung Cancer
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S10 from Decoding B-cell Signatures of Complete Pathologic Response to Perioperative Chemoimmunotherapy in Non–Small Cell Lung Cancer
Supplementary Figure 10. Correlation analysis of deconvolution scores by pathological response.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S10 from Decoding B-cell Signatures of Complete Pathologic Response to Perioperative Chemoimmunotherapy in Non–Small Cell Lung Cancer
Supplementary Figure 10. Correlation analysis of deconvolution scores by pathological response.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S1 from Decoding B-cell Signatures of Complete Pathologic Response to Perioperative Chemoimmunotherapy in Non–Small Cell Lung Cancer
Techniques performed for each patient and sample
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from Decoding B-cell Signatures of Complete Pathologic Response to Perioperative Chemoimmunotherapy in Non–Small Cell Lung Cancer
Techniques performed for each patient and sample